{"id":5467,"date":"2023-11-03T15:34:50","date_gmt":"2023-11-03T20:34:50","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5467"},"modified":"2025-06-27T11:28:56","modified_gmt":"2025-06-27T16:28:56","slug":"nanoscope-therapeutics-awarded-best-of-show-for-retina-at-eyeceleratoraao-2023","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2023\/11\/03\/nanoscope-therapeutics-awarded-best-of-show-for-retina-at-eyeceleratoraao-2023\/","title":{"rendered":"Nanoscope Therapeutics recibe el premio 'Best of Show' para retina en Eyecelerator@AAO 2023"},"content":{"rendered":"
\n

<\/h1>\n<\/div>\n
\n
\n
\n
\n

DALLAS, TX (3 de noviembre de 2020) - Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda en etapa cl\u00ednica que desarrolla terapias gen\u00e9ticas para enfermedades hereditarias de la retina y degeneraciones maculares relacionadas con la edad (DMAE), recibi\u00f3 el premio "Best of Show for Retina" en Eyecelerator@AAO2023. El premio fue entregado al director m\u00e9dico de Nanoscope, Samuel Barone, MD, por su presentaci\u00f3n durante el Retina Showcase del evento. En su presentaci\u00f3n, el Dr. Barone mostr\u00f3 la plataforma Multi-Characteristic Opsin de la compa\u00f1\u00eda y su potencial para restaurar la visi\u00f3n seg\u00fan datos cl\u00ednicos recientes en pacientes con enfermedades degenerativas retinianas avanzadas.<\/p>\n

\"\"
Sam Barone, MD, Director M\u00e9dico de Nanoscope Therapeutics, recibe el premio "Mejor producto de la feria - Retina" durante Eyecelerator@AAO2023 en San Francisco, el 2 de noviembre de 2023.<\/figcaption><\/figure>\n

El destinatario del premio Best of Show se elige mediante votaci\u00f3n de los asistentes a la conferencia. \u201cEstamos encantados y honrados por este reconocimiento\u201d, afirm\u00f3 Sulagna Bhattacharya, directora ejecutiva. \u201cEs muy especial porque proviene de nuestra propia comunidad de retina. Os agradecemos a todos por el \u00e1nimo. Significa mucho para todo nuestro equipo\u201d.<\/p>\n

\u201cLa experiencia del paciente fue el eje central de mi presentaci\u00f3n, y agradezco el reconocimiento a nuestro trabajo para marcar la diferencia en sus vidas\u201d, dijo Samuel Barone, director m\u00e9dico.<\/p>\n

\"\"
Los directivos de Nanoscope Therapeutics celebran el premio "Mejor de la Exposici\u00f3n" en Eyecelerator. De izquierda a derecha: Jared Stephens, vicepresidente de Estrategia y Negocios; Samarendra Mohanty, cofundador y presidente; Sam Barone, director m\u00e9dico; Sulagna Bhattacharya, directora ejecutiva; Michael Marquez, director financiero.<\/figcaption><\/figure>\n

Eyecelerator@AAO2023 se llev\u00f3 a cabo el 2 de noviembre de 2023 antes de la Reuni\u00f3n Anual de la Academia Estadounidense de Oftalmolog\u00eda en San Francisco. Eyecelerator se centra en tendencias emergentes, avances e innovaciones en el cuidado de la vista.<\/p>\n

Acerca de Nanoscope Therapeutics Inc.
\n<\/strong>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas que restauran la vista y son independientes de los genes para los millones de pacientes cegados por enfermedades hereditarias de la retina, para las cuales no existe cura. El activo principal de la compa\u00f1\u00eda, MCO-010, inform\u00f3 recientemente los resultados principales del ensayo cl\u00ednico RESTORE Fase 2b, multic\u00e9ntrico, aleatorizado, de doble enmascaramiento y controlado de forma simulada en los EE. UU. para la retinosis pigmentaria (NCT04945772<\/a>). La compa\u00f1\u00eda tambi\u00e9n complet\u00f3 recientemente su visita de fin de estudio para el ensayo de fase 2 STARLIGHT de la terapia MCO-010 en pacientes Stargardt (NCT05417126<\/a>). MCO-010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y designaciones de medicamento hu\u00e9rfano de la FDA tanto para la retinitis pigmentosa como para Stargardt. Los activos precl\u00ednicos incluyen la terapia g\u00e9nica MCO-020 administrada con l\u00e1ser no viral para la atrofia geogr\u00e1fica.<\/p>\n

\u00a0<\/strong><\/p>\n

Contacto de inversores:<\/b>
Socios Argot
212-600-1902
PR@nanostherapeutics.com<\/a><\/p>\n

FUENTE Terap\u00e9utica del Nanoscopio<\/p>\n<\/div>\n<\/div>\n<\/section>\n<\/article>","protected":false},"excerpt":{"rendered":"

DALLAS, TX (November 3, 2020) \u2014 Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), has been awarded \u201cBest of Show for Retina\u201d at Eyecelerator@AAO2023. The award was presented to Nanoscope\u2019s Chief Medical Officer, Samuel Barone, MD, for his presentation during the event\u2019s Retina Showcase.\u00a0 […]<\/p>\n","protected":false},"author":6,"featured_media":5469,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5467","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics Awarded \u2018Best of Show\u2019 for Retina at Eyecelerator@AAO 2023 - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2023\/11\/03\/nanoscope-therapeutics-awarded-best-of-show-for-retina-at-eyeceleratoraao-2023\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Awarded \u2018Best of Show\u2019 for Retina at Eyecelerator@AAO 2023 - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2023\/11\/03\/nanoscope-therapeutics-awarded-best-of-show-for-retina-at-eyeceleratoraao-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-03T20:34:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T16:28:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/11\/NSCOPE_team_eyecelerator_bestofshow.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1352\" \/>\n\t<meta property=\"og:image:height\" content=\"1077\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/09\/NSCOPE_LI_Barone_final2.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/11\\\/03\\\/nanoscope-therapeutics-awarded-best-of-show-for-retina-at-eyeceleratoraao-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/11\\\/03\\\/nanoscope-therapeutics-awarded-best-of-show-for-retina-at-eyeceleratoraao-2023\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Awarded \u2018Best of Show\u2019 for Retina at Eyecelerator@AAO 2023\",\"datePublished\":\"2023-11-03T20:34:50+00:00\",\"dateModified\":\"2025-06-27T16:28:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/11\\\/03\\\/nanoscope-therapeutics-awarded-best-of-show-for-retina-at-eyeceleratoraao-2023\\\/\"},\"wordCount\":399,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/11\\\/03\\\/nanoscope-therapeutics-awarded-best-of-show-for-retina-at-eyeceleratoraao-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/NSCOPE_team_eyecelerator_bestofshow.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/11\\\/03\\\/nanoscope-therapeutics-awarded-best-of-show-for-retina-at-eyeceleratoraao-2023\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/11\\\/03\\\/nanoscope-therapeutics-awarded-best-of-show-for-retina-at-eyeceleratoraao-2023\\\/\",\"name\":\"Nanoscope Therapeutics Awarded \u2018Best of Show\u2019 for Retina at Eyecelerator@AAO 2023 - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/11\\\/03\\\/nanoscope-therapeutics-awarded-best-of-show-for-retina-at-eyeceleratoraao-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/11\\\/03\\\/nanoscope-therapeutics-awarded-best-of-show-for-retina-at-eyeceleratoraao-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/NSCOPE_team_eyecelerator_bestofshow.jpg\",\"datePublished\":\"2023-11-03T20:34:50+00:00\",\"dateModified\":\"2025-06-27T16:28:56+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/11\\\/03\\\/nanoscope-therapeutics-awarded-best-of-show-for-retina-at-eyeceleratoraao-2023\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/11\\\/03\\\/nanoscope-therapeutics-awarded-best-of-show-for-retina-at-eyeceleratoraao-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/11\\\/03\\\/nanoscope-therapeutics-awarded-best-of-show-for-retina-at-eyeceleratoraao-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/NSCOPE_team_eyecelerator_bestofshow.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/NSCOPE_team_eyecelerator_bestofshow.jpg\",\"width\":1352,\"height\":1077},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/11\\\/03\\\/nanoscope-therapeutics-awarded-best-of-show-for-retina-at-eyeceleratoraao-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Awarded \u2018Best of Show\u2019 for Retina at Eyecelerator@AAO 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics recibe el premio "Mejor producto de la feria" en la categor\u00eda de retina en Eyecelerator@AAO 2023 - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2023\/11\/03\/nanoscope-therapeutics-awarded-best-of-show-for-retina-at-eyeceleratoraao-2023\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics Awarded \u2018Best of Show\u2019 for Retina at Eyecelerator@AAO 2023 - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2023\/11\/03\/nanoscope-therapeutics-awarded-best-of-show-for-retina-at-eyeceleratoraao-2023\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2023-11-03T20:34:50+00:00","article_modified_time":"2025-06-27T16:28:56+00:00","og_image":[{"width":1352,"height":1077,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/11\/NSCOPE_team_eyecelerator_bestofshow.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/09\/NSCOPE_LI_Barone_final2.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2023\/11\/03\/nanoscope-therapeutics-awarded-best-of-show-for-retina-at-eyeceleratoraao-2023\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2023\/11\/03\/nanoscope-therapeutics-awarded-best-of-show-for-retina-at-eyeceleratoraao-2023\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Awarded \u2018Best of Show\u2019 for Retina at Eyecelerator@AAO 2023","datePublished":"2023-11-03T20:34:50+00:00","dateModified":"2025-06-27T16:28:56+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2023\/11\/03\/nanoscope-therapeutics-awarded-best-of-show-for-retina-at-eyeceleratoraao-2023\/"},"wordCount":399,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2023\/11\/03\/nanoscope-therapeutics-awarded-best-of-show-for-retina-at-eyeceleratoraao-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/11\/NSCOPE_team_eyecelerator_bestofshow.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2023\/11\/03\/nanoscope-therapeutics-awarded-best-of-show-for-retina-at-eyeceleratoraao-2023\/","url":"https:\/\/nanostherapeutics.com\/2023\/11\/03\/nanoscope-therapeutics-awarded-best-of-show-for-retina-at-eyeceleratoraao-2023\/","name":"Nanoscope Therapeutics recibe el premio "Mejor producto de la feria" en la categor\u00eda de retina en Eyecelerator@AAO 2023 - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2023\/11\/03\/nanoscope-therapeutics-awarded-best-of-show-for-retina-at-eyeceleratoraao-2023\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2023\/11\/03\/nanoscope-therapeutics-awarded-best-of-show-for-retina-at-eyeceleratoraao-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/11\/NSCOPE_team_eyecelerator_bestofshow.jpg","datePublished":"2023-11-03T20:34:50+00:00","dateModified":"2025-06-27T16:28:56+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2023\/11\/03\/nanoscope-therapeutics-awarded-best-of-show-for-retina-at-eyeceleratoraao-2023\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2023\/11\/03\/nanoscope-therapeutics-awarded-best-of-show-for-retina-at-eyeceleratoraao-2023\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2023\/11\/03\/nanoscope-therapeutics-awarded-best-of-show-for-retina-at-eyeceleratoraao-2023\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/11\/NSCOPE_team_eyecelerator_bestofshow.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/11\/NSCOPE_team_eyecelerator_bestofshow.jpg","width":1352,"height":1077},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2023\/11\/03\/nanoscope-therapeutics-awarded-best-of-show-for-retina-at-eyeceleratoraao-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Awarded \u2018Best of Show\u2019 for Retina at Eyecelerator@AAO 2023"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5467","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5467"}],"version-history":[{"count":2,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5467\/revisions"}],"predecessor-version":[{"id":9064,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5467\/revisions\/9064"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5469"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5467"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5467"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5467"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}